In this last of a comprehensive series of four Homerun Slides sets on SGLT-2 inhibitors, we delve deeper into how this drug class can work in challenging patient populations, incuding older and renally-impaired patients. In addition, the beneficial effects on weight and blood pressure are discussed…. To download the complete …
Read More »Daily Archives: Aug 20, 2014
Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 3
In this third set of a series of four Homerun Slides on SGLT-2 inhibitor medications, we cover LX4211, an SGLT-1 and SGLT-2 dual inhibitor, and then explore some of the safety concerns around SGLT-2 inhibitors including the safety of this drug class for older patients. We also review some of …
Read More »Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 2
In this second set of a comprehensive four-part series of Homerun Slides on SGLT-2 inhibitors, we review some of the data of the second and third approved SGLT-2 inhibitors in the U.S., dapagliflozin (Farxiga) and empagliflozin (Jardiance), along with the Durability and Limitations of this drug class…. To download this …
Read More »Improving Outcomes with SGLT-2 Inhibitors in Challenging T2DM Patients, Part 1
In this first of a series of four sets of Homerun Slides, we review the basics of SGLT-2 inhibitors incuding Mode of Action, and Efficacy. and then look at how Canagliflozin has worked in poorly controlled type 2 diabetes patients…. To download the complete set in PowerPoint (.ppt) format, just …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.